Pharmaceutical Spending and Biologics

Biologic drugs, which are one of the highest growing market segments in Canada, are now facing competition from emerging biosimilar products.1

An assessment of biosimilars currently available in Canada shows that biosimilars are offered at a reduced price, compared with the originator biologic.1

In 2017, biologics in Canada accounted for $7.6 billion in sales1*

 

BIOLOGICS HAVE BEEN ONE OF THE FASTEST GROWING SEGMENTS IN PHARMACEUTICAL SPENDING1*

In 2017:

sales growth was double that of total drug expenditures1*

  • Biologics experienced 10.7% growth compared to 5.3% growth for total prescription drug expenditures1*

Biologics represented in Canada2:

  • 35.5% of total brand prescription sales in dollars*†
  • Included 7 out of the top 10 pharmaceutical brands
Footnote:

*Clinical significance unknown.

†For the 12 months ending December 2017.

References:

1. IQVIA. PharmaFocus 2021 Update. Dec., 2017. 2. Health Canada. Drugs and Health Products. Fact Sheet: Biosimilars. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/biosimilars-biosimilaires-qa-qr-eng.php. Accessed on Feb 6, 2017. 3. Health Canada. Potential Savings from Biosimilars in Canada. PMPRB. April 27, 2017

Learn more about biosimilars in Canada.
Watch the video
Learn more about demonstrating similarity and pharmaceutical spending for biologics in Canada.
More Information